Watch Longevity — peptide industry news, explained simply

Monday, May 4, 2026

Peptide industry news

placeholder

NOTABLE55

COMMERCIALLimited grounding

Lilly’s Strong GLP-1 Results Signal Robust Market Growth for Novo Nordisk says Barclays - Investing.com

Analysis

Barclays reads Lilly's GLP-1 strength as a rising-tide signal for Novo Nordisk, framing the obesity market as expanding rather than zero-sum.

Barclays cites Lilly's strong GLP-1 results as supportive of Novo Nordisk's outlook
Note frames GLP-1 category growth as benefiting both incumbents

$LLY $NVO

glp-1 Eli Lilly Novo Nordisk Barclays

Novo Nordisk News3d

Read

Week in Review

Where the industry is moving

FDA moves to permanently shut compounded GLP-1 channel

FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, signaling no appetite for compounded GLP-1s and intensifying enforcement against compounders like Empower.

Where it leads

If finalized, branded supply from Lilly and Novo absorbs the redirected demand; the Empower ruling shows courts will still litigate compounders case-by-case rather than wholesale shutdown.

Based on 23 stories this week

Semaglutide loss-of-exclusivity begins in Canada

Health Canada cleared first and second generic semaglutides from Apotex and Dr. Reddy's, framed by observers as a G7 test case for Novo's Ozempic franchise; Novo simultaneously cut US list prices for Ozempic and Wegovy by up to 50%.

Where it leads

Generic entry in one major market plus a 50% US list-price cut points to accelerating margin compression on Novo's flagship franchise as more semaglutide generics queue globally.

Based on 17 stories this week

Obesity race fragments into pills, dual agonists, amylin

Lilly's oral Foundayo hit ~20,000 patients while reportedly trailing Novo's rebranded Ozempic pill; Boehringer/Zealand's survodutide posted 16.6% Phase 3 weight loss; Amgen launched MariTide switch trials and Lilly's CEO publicly jabbed AbbVie and Pfizer amylin programs.

Where it leads

GLP-1 monotherapy injectables are no longer the only battleground — competition is splintering into oral GLP-1s, GLP-1/glucagon dual agonists, monthly dosing, and amylin combos, with Lilly and Novo defending on multiple fronts at once.

Based on 25 stories this week

Drawn from 100 stories · Generated 7h ago

Inside

Providers

A curated index of vetted peptide sourcing partners — pricing, sourcing notes, and the deals worth your attention.

Read the dispatch →

Partner

Refills

Compounded GLP-1s, fast.

Starts at $159 with free same-day shipping
Telehealth consults & care coaching
No insurance needed

Reader offer

$100 off first order

Visit Refills

The Daily Wire

Critical news, in your inbox.

One email a day with the day's most important peptide-industry stories — explained in plain English. No filler.